Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.» Read More
CNBC's Meg Tirrell reports on how the pharmaceutical industry is dealing with the Alzheimer's epidemic.
Data from a study of Sarepta Therapeutics' experimental drug for Duchenne muscular dystrophy suggest it helped slow declines in walking ability for almost three years.
Narcotics prosecutors say a NYC hospital's former pharmacy chief stole nearly 200,000 oxycodone pills over more than five years.
Six vials of a smallpox virus were discovered to have been misplaced in a FDA lab storage room in Maryland. NBC News reports.
An unconventional but effective treatment against a deadly superbug is raising worries about a possible black market.
Certain areas of the brain have shown links to trading behavior and success, according to new research published Monday.
The largest U.S. pharmacy benefit manager, Express Scripts, is cutting back on compounded medications, saying most are ineffective or overpriced.
Massachusetts is expected to add almost 400 jobs in biotech manufacturing by 2016. CNBC's Mary Thompson reports Quincy College aims to fill some of those jobs with a new program.
CNBC's Mary Thompson reports Quincy College in Massachusetts is training students with hands-on experience for jobs in the biotech industry.
Pfizer paid a "nominal fee" to cover expenses related to the facility inspection, and to obtain a certification, a Pfizer spokeswoman said.
Hedge fund Paulson & Co has amassed a large stake in Allergan and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals.
The U.S. Food and Drug Administration warned that popular acne products can cause rare but serious and life-threatening allergic reactions.
Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.
A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.
CNBC's Meg Tirrell reports the pharmaceutical company has developed a new drug that significantly improves lung function in the treatment of cystic fibrosis.
A U.S. Senate panel asked the Centers for Disease Control and Prevention to explain the breach that exposed many to live anthrax, a deadly pathogen.
Vertex's Kalydeco was the first medicine to address the underlying genetic cause. A new drug combination, Kalydeco and Lumacaftor, is designed to treat many additional cases.
Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.
Genetics startup 23andMe said it is one step closer to resuming sales of its full-fledged health product.
Researchers have discovered that an FDA-approved arthritis drug may hold the secret to curing hairlessness.
Get the best of CNBC in your inbox